Patient enrollment now complete in DNL343 arm of HEALEY ALS trial

Patient enrollment is now complete in an arm of the HEALEY ALS platform trial that’s testing Denali Therapeutics‘ DNL343 for the treatment of adults with amyotrophic lateral sclerosis (ALS). The HEALEY platform trial (NCT04297683), led by the Sean M. Healey & AMG Center…

Epigenetic changes — chemical modifications in DNA that alter gene activity — in nerve cells from people with amyotrophic lateral sclerosis (ALS) may be associated with the rate of disease progression, a study suggested. Changes in certain regions of a patient’s nerve cell genome were able “to predict ALS…

Alejandra Zeballos, a PhD student in bioengineering at the University of Illinois Urbana-Champaign, was awarded the 2024 Illinois Innovation Award for her work on next-generation therapies to advance the treatment of amyotrophic lateral sclerosis (ALS). Zeballos, a member of the Gaj Lab, has been working…

PrimeC, a treatment candidate for amyotrophic lateral sclerosis (ALS), was found to significantly slow disease progression in certain subgroups of patients in the ongoing PARADIGM Phase 2b trial, according to new data announced by its developer NeuroSense Therapeutics. Benefitting most were people at high risk of rapid disease…

As a caregiver for my husband, Todd, who has ALS, I’ve experienced numerous traumas in the 14 years that we’ve been living with the disease. Our lives were shattered with Todd’s diagnosis, which occurred when our daughter was 4 and our son was 9 months old. I…

University of Michigan neurologist Eva Feldman was recently recognized with the 2024 Sheila Essey Award for her groundbreaking research on the biological processes that drive the onset of amyotrophic lateral sclerosis (ALS) and its progression. The award, announced at the American Academy of Neurology (AAN) 2024 Annual Meeting, recognizes…

It’s time to fill the balloons, hang the streamers, and invite our friends and family to join us for a summer full of fun ALS awareness events! Did you know that we’re also celebrating 32 years since May was designated as ALS Awareness Month and that 2024 is…

The ALS Multidisciplinary Clinic at the University of Cincinnati Gardner Neuroscience Institute in Ohio has been gifted $13.5 million to advance its research and patient care initiatives related to amyotrophic lateral sclerosis (ALS). The donation comes from the estate of Hugh H. Hoffman, who earned a degree from the…

The Tambourine ALS Breakthrough Research Fund has committed more than $5 million in funding to eight research projects aiming to better understand, diagnose, and treat amyotrophic lateral sclerosis (ALS). A first call for proposals was launched in May 2023 by Tambourine Philanthropies, a charitable foundation established by…